SEC Form 4 · accession 0001140361-18-014331
OncoMed Pharmaceuticals Inc · OMED
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yvonne Li
Officer — See Remarks
Period of report
Mar 18, 2018
Accepted (ET)
Mar 20, 2018 · 5:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001302573
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $2.98 | Mar 18, 2018 | A | 75,000 | A | — | Mar 17, 2028 | Common Stock | 75,000 | 75,000 | D |
Explanation of responses
- F1The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of March 18, 2018, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
Remarks
Vice President, Finance, Controller and Administration